Showing papers by "Mariell Jessup published in 2007"
TL;DR: The ultimate intent of this document is to provide an understanding of the range of acceptable approaches for the use of EMB while recognizing that individual patient care decisions depend on factors not well reflected in the published literature, such as local availability of specialized facilities, cardiovascular pathology expertise, and operator experience.
Abstract: The role of endomyocardial biopsy (EMB) in the diagnosis and treatment of adult and pediatric cardiovascular disease remains controversial, and the practice varies widely even among cardiovascular centers of excellence. A need for EMB exists because specific myocardial disorders that have unique prognoses and treatment are seldom diagnosed by noninvasive testing.1 Informed clinical decision making that weighs the risks of EMB against the incremental diagnostic, prognostic, and therapeutic value of the procedure is especially challenging for nonspecialists because the relevant published literature is usually cited according to specific cardiac diseases, which are only diagnosed after EMB. To define the current role of EMB in the management of cardiovascular disease, a multidisciplinary group of experts in cardiomyopathies and cardiovascular pathology was convened by the American Heart Association (AHA), the American College of Cardiology (ACC), and the European Society of Cardiology (ESC). The present Writing Group was charged with reviewing the published literature on the role of EMB in cardiovascular diseases, summarizing this information, and making useful recommendations for clinical practice with classifications of recommendations and levels of evidence.
The Writing Group identified 14 clinical scenarios in which the incremental diagnostic, prognostic, and therapeutic value of EMB could be estimated and compared with the procedural risks. The recommendations contained in the present joint Scientific Statement are derived from a comprehensive review of the published literature on specific cardiomyopathies, arrhythmias, and cardiac tumors and are categorized according to presenting clinical syndrome rather than pathologically confirmed disease. The ultimate intent of this document is to provide an understanding of the range of acceptable approaches for the use of EMB while recognizing that individual patient care decisions depend on factors not well reflected in the published literature, such as local availability of specialized facilities, cardiovascular pathology expertise, and operator experience. The use of EMB …
1,050 citations
TL;DR: In decompensated HF, ultrafiltration safely produces greater weight and fluid loss than intravenous diuretics, reduces 90-day resource utilization for HF, and is an effective alternative therapy.
956 citations
TL;DR: The ultimate intent of this document is to provide an understanding of the range of acceptable approaches for the use of EMB while recognizing that individual patient care decisions depend on factors not well reflected in the published literature, such as local availability of specialized facilities, cardiovascular pathology expertise, and operator experience.
Abstract: The role of endomyocardial biopsy (EMB) in the diagnosis and treatment of adult and pediatric cardiovascular disease remains controversial, and the practice varies widely even among cardiovascular centers of excellence. A need for EMB exists because specific myocardial disorders that have unique prognoses and treatment are seldom diagnosed by noninvasive testing.1 Informed clinical decision making that weighs the risks of EMB against the incremental diagnostic, prognostic, and therapeutic value of the procedure is especially challenging for nonspecialists because the relevant published literature is usually cited according to specific cardiac diseases, which are only diagnosed after EMB. To define the current role of EMB in the management of cardiovascular disease, a multidisciplinary group of experts in cardiomyopathies and cardiovascular pathology was convened by the American Heart Association (AHA), the American College of Cardiology (ACC), and the European Society of Cardiology (ESC). The present Writing Group was charged with reviewing the published literature on the role of EMB in cardiovascular diseases, summarizing this information, and making useful recommendations for clinical practice with classifications of recommendations and levels of evidence.
The Writing Group identified 14 clinical scenarios in which the incremental diagnostic, prognostic, and therapeutic value of EMB could be estimated and compared with the procedural risks. The recommendations contained in the present joint Scientific Statement are derived from a comprehensive review of the published literature on specific cardiomyopathies, arrhythmias, and cardiac tumors and are categorized according to presenting clinical syndrome rather than pathologically confirmed disease. The ultimate intent of this document is to provide an understanding of the range of acceptable approaches for the use of EMB while recognizing that individual patient care decisions depend on factors not well reflected in the published literature, such as local availability of specialized facilities, cardiovascular pathology expertise, and operator experience. The use of EMB …
848 citations
TL;DR: The role of endomyocardial biopsy (EMB) in the diagnosis and treatment of adult and pediatric cardiovascular disease remains controversial, and the practice varies widely even among cardiovascular centers of excellence as discussed by the authors.
494 citations
TL;DR: The results of the Acorn trial support the hypothesis that preventing LV remodeling with a CSD favorably impacts the untoward natural history of heart failure.
130 citations
TL;DR: These results demonstrate that the CorCap Cardiac Support Device has a long-term beneficial impact on LV size and shape in patients with heart failure.
103 citations
TL;DR: Clinicians recognize that in most chronic illnesses, the prognosis is, at best, a guess but that ultimately death is inevitable, however, it is the time course, manner of death, and quality of life along the way that the authors' patients most want to know.
Abstract: “I wanted a perfect ending. Now I’ve learned, the hard way, that some poems don’t rhyme, and some stories don’t have a clear beginning, middle, and end. Life is about not knowing, having to change, taking the moment and making the best of it, without knowing what’s going to happen next. Delicious ambiguity.” — —Gilda Radner US actress and comedienne (1946–1989)
What would you do if you knew you had 6 months to live? How would you choose to spend your time? Would you be willing to try an experimental and risky therapy that might decrease your quality but increase your quantity of life? What would you do if you knew that your patient had 6 months to live despite current clinical stability? Would you tell him? Would you be more or less “aggressive” with treatment options?
Article p 392
Physicians are often faced with life-or-death situations. In the abstract, we can conceptualize and rationalize biology, but the ability to convert our understanding of the natural course of a disease to a useful, sensitive, and realistic conversation with a patient and his or her family is something with which few are comfortable. This is especially true when the patient is awake, alert, and ambulatory. The word “prognosis” is derived from Greek, defined as “a forecast of the probable course or outcome of a disease.”1 Clinicians recognize that in most chronic illnesses, the prognosis is, at best, a guess but that ultimately death is inevitable. However, it is the time course, manner of death, and quality of life along the way that our patients most want to know. Physicians fear that delivering the news of a grave prognosis will send the patient into despair and rob them of any hope. Many clinicians still see death as professional failure and therefore …
31 citations
TL;DR: The development of clinical or practice guidelines is thought to be a successful strategy for improving quality of care and many professional organizations, societies, institutions of health care or policy, and even countries have published practice guidelines.
13 citations
TL;DR: The review summarizes the types of rejection that occur after transplant surgery, maintenance immunosuppression to prevent rejections and treatment regimens useful when rejection occurs.
Abstract: Purpose of reviewCardiac transplantation continues to be the treatment of choice for suitable patients with refractory heart failure. Patients referred for transplant tend to be older and have additional comorbidities that require newer strategies for subsequent immunosuppression. The review summari
5 citations
TL;DR: This work presents a meta-analysis of data from a 15-year multi-institutional study on heart transplantation that shows clear trends in progression inKI patients and outcomes and calls for further investigation into the mechanisms behind this trend.
Abstract: PROGRESS IN HEART TRANSPLANTATION: RISKIER PATIENTS YET BETTER OUTCOMES: A 15-YEAR MULTI-INSTITUTIONAL STUDY D.O. Taylor, R.N. Brown, M.L. Jessup, R.C. Starling, K.D. Aaronson, B.K. Rayburn, J. Czerr, D.C. Naftel, J.K. Kirklin, the Cardiac Transplant Research Database, Cleveland Clinic, Cleveland, OH; Univ. of Alabama at Birmingham, Birmingham, AL; Univ. of Pennsylvania, Philadelphia, PA; Univ. of Michigan, Ann Arbor, MI
4 citations
TL;DR: This multicenter trial will investigate the efficacy and safety of nesiritide and provide mechanistic insight into benefits of its use for the relief of breathlessness and provide key data for clinical profiles of heart transplant candidates bound to inotropic support.
Journal Article•